{
    "clinical_study": {
        "@rank": "13182", 
        "arm_group": {
            "arm_group_label": "Belotecan and Ifosfamide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of\n      Belotecan and Ifosfamide.\n\n      Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide."
        }, 
        "brief_title": "A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer", 
        "condition": "Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically or cytologically confirmed extensive disease of Small cell lung cancer\n\n          -  no prior chemotherapy or radiotherapy for lung\n\n          -  measurable lesion for RECIST\n\n          -  over 18 years\n\n          -  ECOG 0~2\n\n          -  expected life span more than 3 months\n\n        Exclusion Criteria:\n\n          -  acute or active infection\n\n          -  uncontrolled cerebral nerve symptoms or metastasis\n\n          -  significant myocardial infarction or cardiac disease within 12 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784107", 
            "org_study_id": "2011-GIRBA-2550"
        }, 
        "intervention": {
            "arm_group_label": "Belotecan and Ifosfamide", 
            "intervention_name": "Belotecan and Ifosfamide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ifosfamide", 
                "Isophosphamide mustard", 
                "Belotecan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "SCLC", 
            "belotecan", 
            "Ifosfamide"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "location": {
            "contact": {
                "email": "hkahn@gilhospital.com", 
                "last_name": "Hee Kyung Ahn", 
                "phone": "+82-32-460-3229"
            }, 
            "facility": {
                "address": {
                    "city": "Incheon", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Gachon University Gil Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer", 
        "other_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "measure": "PFS(Progression-Free-Survival)", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }
        ], 
        "overall_contact": {
            "email": "hkahn@gilhospital.com", 
            "last_name": "Hee Kyung Ahn", 
            "phone": "+82-32-460-3229"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MTD (maximal tolerated dose)", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784107"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Gachon University Gil Medical Center", 
            "investigator_full_name": "Eun Kyung Cho", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "DLT(dose-limiting toxicity)", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Gachon University Gil Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gachon University Gil Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}